Almost every autoimmune indication shares the same design problem. The initiating antigen is unknown, so the antigen-specific cells cannot be found reliably and studies fall back on bulk phenotyping. Celiac disease is the exception. The antigen is known, it is available, it can be given deliberately, and the resulting antigen-specific T cells appear in peripheral blood on a schedule.
The antigen is known, which changes everything downstream
The driver in celiac disease is dietary gluten, specifically deamidated gliadin peptides generated by tissue transglutaminase and presented on particular class II molecules. Nothing else in the autoimmune catalogue offers that combination of a defined antigen, a defined presenting molecule and a route of administration.
The consequence is that celiac disease supports experiments that are simply unavailable elsewhere. Antigen-specific CD4 positive T cells can be identified directly with class II tetramers rather than inferred from bulk activation markers, and their frequency can be manipulated on purpose.
HLA-DQ2.5 and DQ8 restriction, and why typing is not optional
The great majority of people with celiac disease carry HLA-DQ2.5, with most of the remainder carrying DQ8. The negative predictive value of carrying neither is high enough that HLA typing functions as an exclusion test in clinical practice. This is one of the strongest genotype to phenotype relationships in autoimmunity.
For a research cohort this has two implications. A celiac donor population that has not been typed at DQ cannot be stratified on the variable that determines which peptides are presented at all. And any tetramer-based work must be matched to the donor’s DQ genotype, because a DQ2.5 restricted reagent will not report on a DQ8 restricted response. High-resolution NGS typing across HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ and HLA-DP is part of donor characterization, so DQ genotype is a selection parameter rather than an afterthought.
The window after gluten challenge
In treated celiac donors on a gluten-free diet, gluten-specific T cells are present at frequencies that are difficult to work with directly. A short, controlled oral gluten challenge mobilises those cells into peripheral blood, where they become detectable and peak around the sixth day after the challenge begins. The cells are activated, they carry gut-homing markers, and they can be captured with DQ-matched tetramers.
That schedule is the single most useful practical fact about this indication. It means a blood draw can be timed to the biology rather than to convenience, which is a luxury that most autoimmune programs do not have.
| Donor state | What the blood contains | Best suited to |
|---|---|---|
| Untreated, newly diagnosed, still consuming gluten | Ongoing systemic response, active serology | Baseline disease characterization and serology work |
| Treated, gluten-free diet, no challenge | Low frequency of antigen-specific cells | Memory phenotype and comparator arms |
| Treated, during a controlled gluten challenge | Mobilised antigen-specific CD4 cells, gut-homing markers | Tetramer work and antigen-specific readouts |
| Diet non-adherent | Intermediate and unpredictable | Little, unless adherence is documented |
Related product
Disease-state PBMCs. PBMCs from donors with a documented diagnosis, across 24 autoimmune and inflammatory indications.
Adherence is a cohort variable, not a footnote
Because treatment is dietary rather than pharmacological, compliance varies and is self-reported. A donor described as treated may be strictly adherent or intermittently exposed, and those two produce different circulating profiles. Serology helps, since anti-transglutaminase antibody titres fall on a genuinely gluten-free diet and remain raised with continued exposure, but the correlation is imperfect over short intervals.
Recording diet duration and recent serology at collection costs very little and prevents a category of result that is otherwise uninterpretable.
Serology as a filter, with its limits
Anti-tissue transglutaminase IgA is the standard serological marker, with endomysial antibodies used as a more specific confirmatory test and deamidated gliadin peptide antibodies retained mainly for IgA deficient individuals. Selective IgA deficiency is more common in celiac disease than in the general population, which is a real source of false negative screening and worth checking when a donor’s history and serology disagree.
Refractory disease is a different population
A minority of patients continue to have symptoms and villous atrophy despite strict dietary adherence. Refractory celiac disease is conventionally divided into two types. Type I carries a normal intraepithelial lymphocyte phenotype. Type II is defined by a clonal population of intraepithelial lymphocytes with an aberrant phenotype, and it sits on a continuum toward enteropathy-associated T cell lymphoma.
These are not interchangeable with ordinary celiac disease and should never be pooled into a general cohort without being labeled. The clonality that defines type II is a lymphoproliferative feature, and a handful of such donors inside a cohort of a few dozen will distort any repertoire or clonality analysis. If a study is examining T cell receptor repertoire, refractory status is a required exclusion or stratification variable rather than an optional one.
Associated conditions travel with this diagnosis
Celiac disease co-occurs with type 1 diabetes, autoimmune thyroid disease and selective IgA deficiency at rates well above population background, and dermatitis herpetiformis is the cutaneous expression of the same gluten sensitivity. Part of this clustering is genuine shared biology, since the class II haplotypes that carry celiac risk overlap with those carrying risk for type 1 diabetes.
That overlap is worth thinking about carefully when constructing comparator groups. Matching a celiac cohort to healthy donors on DQ genotype produces a cleaner comparison than matching on demographics, but it also selects comparators who carry autoimmune-associated haplotypes. Whether that is the right control depends entirely on whether the question is about genotype or about disease, and deciding that in advance saves an argument at the analysis stage.
Specifying a celiac cohort that answers the question
Disease-state donor material is supplied for research use across 24 autoimmune indications, with a post-thaw viability specification above 80 percent. For celiac disease the parameters that matter most are DQ genotype, treatment status, diet duration, recent serology and, where relevant, position within a challenge protocol. Donor selection can be scoped by disease state, HLA genotype, age, sex, ethnicity, blood type, CMV and EBV status, BMI and smoking status, subject to availability.
Designs that need the same donor before, during and after a challenge depend on repeat collection, which is available for eligible donors and is not a blanket guarantee for every donor or request. A longitudinal celiac protocol is worth scoping before it is finalised, because the timing is the point of the experiment.
Related material: how HLA typing resolution is reported, HLA basics including class II, and the cryopreserved PBMC format.
Frequently asked questions
Why is celiac disease easier to study than other autoimmune conditions?
The driving antigen is known and can be administered deliberately, and the presenting molecules are narrowly restricted to HLA-DQ2.5 and DQ8. That combination allows antigen-specific T cells to be identified directly with tetramers rather than inferred from bulk activation markers.
When should blood be drawn during a gluten challenge?
Gluten-specific T cells mobilise into peripheral blood after the challenge begins and peak around day six. Sampling is normally timed to that window, which is what makes antigen-specific readouts practical in this indication.
Does the tetramer reagent need to match the donor’s DQ genotype?
Yes. A DQ2.5 restricted tetramer will not report a DQ8 restricted response. Specify DQ genotype at donor selection so the cohort matches the reagents already in the protocol.
Are treated and untreated celiac donors interchangeable?
No. Untreated donors still consuming gluten show an ongoing systemic response and active serology. Treated donors on a gluten-free diet carry far lower frequencies of antigen-specific cells. They answer different questions and should be recorded separately.
How is dietary adherence handled as a variable?
Adherence is self-reported and variable, so it is recorded rather than assumed. Anti-transglutaminase titres fall on a genuinely gluten-free diet and support the history, though the correlation over short intervals is imperfect.
Why does IgA deficiency matter here?
Selective IgA deficiency is more common in celiac disease than in the general population and produces false negative IgA-based serology. Where history and serology disagree, IgA status is worth checking before the donor is excluded.
Can the same donor be sampled across a challenge protocol?
Repeat collection is available for eligible donors, which supports before, during and after designs. It is not guaranteed for every donor or request, so the schedule should be agreed while the protocol is being written.
Is this material suitable for clinical use?
No. Disease-state donor material is supplied for research use covering discovery, drug screening and biomarker work. Clinical scope requires cGMP material under a separate agreement.
Talk to OrganaBio
Sourcing a celiac disease cohort?
Donor selection can be scoped by disease state, HLA genotype and donor characteristics, subject to availability, and donor-matched plasma, serum and PBMCs are available from the same donor. Tell us the parameters your protocol needs and the scientific team will confirm what can be supplied.
